** U.S.-listed shares of Israel-based drugmaker Teva Pharmaceutical Industries TEVA.TA, TEVA.N rises 6.6% to $17.32 premarket
** TEVA and partner Biotech Alvotech ALVO.O say the U.S. FDA has accepted for review its marketing application for a biosimilar or close copy of Regeneron's REGN.O Eylea
** Co says AVT06 is a proposed biosimilar of Eylea's 2 milligram dose which is used to treat eye disorders like macular degeneration, macular edema and retinopathy
** Co, ALVO expects regulatory decision for AVT06 by Q4 2025
** Some key patents of Eylea are set to expire in 2027, according to a regulatory filing
** ALVO is also developing AVT29, a biosimilar for Eylea HD, a 8 mg dose of the drug
** Amgen AMGN.O will also make its biosimilar version of Eylea available to patients after a U.S. appeals court rejected REGN's request to block its launch
** In the last 12 months, TEVA has risen 32.4%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.